{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000095","form_type":"8-K","ticker":"OSUR","cik":"0001116463","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.466508+00:00","generated_at":"2026-06-27T20:05:56.270707+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OraSure CEO Stephen S. Tang to depart March 31, 2022; gets severance of $1.57M plus equity","bullets":["CEO Stephen Tang's termination without cause effective March 31, 2022; transition period through that date.","Tang receives lump sum severance of $1,569,614 (18 months salary plus target bonus).","50% of unvested time-based RSUs and PVRUs vest at termination; 2022 LTIP award of $834,909 vests at end.","Lisa Nibauer becomes President of Diagnostics; salary raised to $460,000 and bonus target to 50%.","Kathleen G. Weber becomes President of Molecular Solutions; salary raised to $460,000 and bonus target to 50%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000095","json":"https://secwatch.observer/filing/0000950170-22-000095.json","markdown":"https://secwatch.observer/filing/0000950170-22-000095.md","text":"https://secwatch.observer/filing/0000950170-22-000095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/osur-20211231.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:05:56.270707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44dfe2ce4e","claim":"Stephen S. Tang departed as President and Chief Executive Officer at ORASURE TECHNOLOGIES INC.","evidence_excerpt":"Stephen S. Tang, the Company’s President and Chief Executive Officer, will be leaving the Company as of March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"leaving"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8c00c716da","claim":"Lisa Nibauer changed role as President of Diagnostics at ORASURE TECHNOLOGIES INC.","evidence_excerpt":"Effective as of December 31, 2021, Lisa Nibauer, the Company’s current Executive Vice President, Business Unit Leader, Diagnostics, will become President of Diagnostics.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President of Diagnostics"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}